BioAge Labs (BIOA) Net Income towards Common Stockholders (2023 - 2026)

BioAge Labs has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$22.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 70.4% year-over-year to -$22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.0 million (up 35.26% YoY) and the FY2025 annual result came in at -$125.9 million, down 56.33% from the prior year.
• Net Income towards Common Stockholders declined to -$22.2 million in Q1 2026 per BIOA's latest filing, from -$15.7 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$11.8 million in Q3 2023 and troughed at -$82.2 million in Q3 2024.
• A 4-year average of -$25.1 million and a median of -$15.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders plunged 597.18% in 2024, then jumped 65.27% in 2025.
• Over 4 years, Net Income towards Common Stockholders stood at -$15.8 million in 2023, then slumped by 97.86% to -$31.2 million in 2024, then soared by 49.66% to -$15.7 million in 2025, then sank by 41.33% to -$22.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$22.2 million, -$15.7 million, and -$28.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.